Leo Pharma reaches endpoints in phase III hand eczema trial
Topline data from a phase III trial of delgocitinib, a JAK inhibitor treatment for severe chronic hand eczema, was positive for Leo Pharma.
by ulrich quistgaard, translated by catherine brett
Leo Pharma attained all primary and secondary endpoints in its phase III trial of delgocitinib within the moderate to severe chronic hand eczema indication, the firm reveals in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Former US head of Leo Pharma gets board seat at Kempharm
For subscribers
UK authority warns of Dupixent adverse effects
For subscribers
Leo Pharma's label extension wish granted
For subscribers
